Joya E Dagher

Learn More
This study was designed to determine the safety and efficacy of the combination therapy of gemcitabine plus carboplatin when used as a second-line treatment in patients with metastatic breast cancer (MBC). From February 2002 to May 2003, 30 previously treated patients with adenocarcinoma of the breast received gemcitabine 1000 mg/m2 on days 1 and 8 plus(More)
817 Background: The combination of vinorelbine (N) and capecitabine (C) has demonstrated to be active and safe regimen for advanced breast cancer (ABC) (Ghosn; ASCO 03); capecitabine and docetaxel (D) combination in anthracycline failure has demonstrated an interesting outcomes, but with high toxicity profile. In order to improve patient clinical benefit by(More)
4704 Background: To assess the efficacy of the association of gemcitabine, carboplatine and paclitaxel given in a weekly basis for locally advanced or metastatic urothelial cancer as first line therapy. Other objectives were response duration and the toxicity profile. METHODS This phase II study included gemcitabine: 800mg/m2, carboplatine: AUC = 2 and(More)
4706 Background: Docetaxel and estramustine phosphate have been shown to have synergistic and significant activity in patients with MAIP. Zoledronic acid is a third generation biphosphonate, which reduces skeletal events by inhibiting bone destruction in MAIP patients. METHODS We conducted a phase II trial with the combination of estramustine, zoledronic(More)
  • 1